
The Journey to Disclosure and Visibility
At the start of your HIV journey, it's normal to be focused on surviving these challenges.
As the basics of managing your diagnosis unfold, there's much also happening inside you – feelings and emotions that can be overwhelming. Feeling angry, confused, sad, hopeless, and frightened are to be expected. Unpacking those feelings is important.
There's a lot of change and new information to digest as well. Move at your own pace. Being patient, persistent, and honest with yourself goes a long way in helping you adapt.
Regardless of how it looks or how long it takes to adjust, life with HIV can be rewarding and empowering. What seemed impossible ends up in your rear view mirror. Day by day, month by month, year by year, you can build mental and emotional strength. That strength will always be useful and necessary.
When things start to level out for you, it may help to figure out how and when to share your experience. Finding your level of comfort with talking about your status takes time. This varies from person to person. But once you've become more secure in the basics of what it means to live with HIV, opening up is often easier. There's no right or wrong way to approach this.
Opening up about your status may happen with someone close to you, with whom you feel safe. Or it could happen in a support group, sharing with others who can relate to what you're going through and experienced.
Choosing to process some (or all) of what's happened with a mental health professional could be the way to go. For some, sharing publicly about their life with HIV is beneficial. This could happen through speaking engagements, artistic performances, or writing. In my case, after a few years with HIV, I tried each of the above methods. They were helpful for me, albeit at different points in the first 10 years of my HIV journey.
If you choose to go share your experiences, it's important to be mindful of potential risks.
Stigma, ignorance, fear, and misinformation are prevalent. In some instances, they've led to harmful outcomes. While this shouldn't deter you from being open about your status or being more visible, if that's what you want, it's important to consider how visible you choose to be, and with whom.
When it comes to HIV and how much of your life it impacts, your decision about disclosure and visibility should be made carefully. But the choice is an extremely personal one. It's not for everyone, which is OK.
Whether you choose to navigate their HIV journey privately, publicly, or somewhere in between, the important thing is you get the treatment, care, and support you need and deserve.
Regardless of what you choose, the goal is living a long, healthy, and prosperous life while feeling as safe as possible.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT
Enovis Corporation (NYSE:ENOV) is one of the best undervalued medical device stocks to buy now. In a report released on July 8, Vijay Kumar from Evercore ISI maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $46.00. A patient recieving cold therapy treatment using the company's products. The company reported continued commercial momentum in fiscal Q1 2025 results, with net sales for the quarter reaching $559 million and reported an 8% growth on a reported basis and 9% rise on a comparable basis from the same quarter last year. Reconstructive sales for the quarter rose 11% year-over-year on a reported basis. Enovis Corporation's (NYSE:ENOV) fiscal Q1 2025 results show a rebound in growth in Recon, net sales for which grew 11% on a reported and comparable basis. The company also showed accelerating momentum in new product introductions and continued execution in P&R, reflecting a 5% growth on a reported basis and 7% on a comparable growth basis. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
4 minutes ago
- Yahoo
Truist Financial Remains Bullish on AdaptHealth (AHCO)
AdaptHealth Corp. (NASDAQ:AHCO) is one of the best undervalued medical device stocks to buy now. In a report released on July 1, David S Macdonald from Truist Financial maintained a Buy rating on AdaptHealth Corp. (NASDAQ:AHCO) without a price target. A healthcare professional wearing a face mask and surgical gloves operating a medical device in a clinical setting. AdaptHealth Corp. (NASDAQ:AHCO) reported $95.5 million in cash flow from operations in fiscal Q1 2025, an increase from $49.0 million. Free cash flow for the quarter reached negative $0.1 million, compared to negative $38.9 million previously. Net revenue for the quarter, however, underwent a 1.8% decline to $777.9 million. AdaptHealth Corp. (NASDAQ:AHCO) provides home healthcare equipment, supplies, and related services. The company's focus is on sleep therapy equipment for obstructive sleep apnea, oxygen, and related chronic therapy services, HME medical devices and supplies for wound care, diabetes, urological, and more. While we acknowledge the potential of AHCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed's comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants. A research scientist in a laboratory holding a vial of a biotechnology drug. The analyst told investors in a research note that this development is significant for Vaxcyte, Inc. (NASDAQ:PCVX), as its pneumococcal vaccine candidates contain aluminum adjuvant at levels similar to those found in Merck's Vaxneuvance and Pfizer's Prevnar 20. The firm stated that aluminum adjuvants are present in several vaccines recommended by the Centers for Disease Control and Prevention for infants and children and have been used widely since the 1930s. It added that the FDA's work shows that aluminum exposure from vaccines is safe, and sees the 'preponderance of evidence' as supporting the use of aluminum adjuvants in vaccines. Mizuho thus stated that if a review of licensed vaccines containing aluminum adjuvant is carried out, it 'will prove this out.' Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques. While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data